MedInvest Oncology Investor Conference, in Palo Alto, CA, on December 5-6, 2023

connect with GenEndeavor
Written By Ricardo Mancebo

We are thrilled to announce @GenEndeavor’s participation in the upcoming MedInvest Oncology Investor Conference, in Palo Alto, CA, on December 5-6, 2023.

At the event, GenEndeavor will showcase our molecular diagnostics technology platform, which lowers the limit of detection of rare mutations and rapidly identifies pathogens for sensitive and real-time genetic and infectious disease detection. GenEndeavor’s current focus is to translate this new platform into an early-detection ovarian cancer screening test.

If you're attending the conference, we would like to connect with you and have discussions on how we can partner in developing breakthrough technology for the early detection of ovarian cancer. #MedInvestOncology #LifeSciences #OncologyInvesting #InnovationInHealthcare

Ricardo Mancebo
Previous

Call for applications: Senior Research Associate
Next

Jill Biden Announces Women's Health Research Initiative